CGEM - NASDAQ

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%

HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$934.78M

EPS-3.7200

P/E Ratio-4.09

Earnings Date08/06/2026

cgem

Depreciation and Amortization

Last Annual Value

311.00K

3-Year CAGR

50%

5-Year CAGR

38%

10-Year CAGR

22%

Adjust for Inflation

Cullinan Therapeutics, Inc. Competitors Analysis of Depreciation and Amortization

CGEM · NASDAQ

Company	Depreciation and Amortization	CAGR 3Y	CAGR 5Y	CAGR 10Y
Cullinan Therapeutics, Inc. NASDAQ:CGEM	311.00K	0.1%	42.5%	N/A
Varex Imaging Corporation NASDAQ:VREX	27.20M	-6.4%	-6.1%	N/A
CeriBell, Inc. NASDAQ:CBLL	-670.00K	N/A	N/A	N/A
Enhabit, Inc. NYSE:EHAB	22.50M	-10.0%	-9.4%	N/A
Standard BioTools Inc. NASDAQ:LAB	1.72M	-51.7%	-36.2%	-20.9%
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	208.00K	-32.2%	-17.3%	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	1.20M	-30.3%	3.8%	N/A
Omeros Corporation NASDAQ:OMER	964.00K	1.6%	-7.0%	12.4%

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $15.21

Related Guides

Blog Categories

Continue your CGEM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.